Business Development

BD/partnering opportunities with biopharma/platform companies

  • Collaborate with biopharmaceutical companies in the development of “SELECT” companion diagnostics to assist with treatment decisions based on the efficacy and/or safety of a specific compound for specific population.
  • Identify new molecular diagnostic tests utilizing our SNAQ technology on ‘SELECT” platforms by translating a biomarker to a diagnostic.
  • Develop and leverage strategic collaborations with instrument and platform companies to increase SNAQ technology market penetration.
  • Strengthen development & applications for new oncology drug products and companion diagnostics by providing standardized data with “Intrinsic Quality Control”.

All inquires and communications regarding Accugenomics should be directed to Nick Lazaridis at